K. Imai

Oncology · with Takaoka · 2006

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom K. Imai trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Baselga
  2. P. Carter
  3. G. A. Lazar
  4. Zachary A. Knight
  5. R. Nahta
  6. J. Mendelsohn
  7. A. Arora

Papers from K. Imai's perspective

Ordered by how strongly the researchers K. Imai trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Monoclonal antibody successes in the clinic (Nature Biotechnology)
  2. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. (Journal of Clinical Oncology)
  3. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
  4. Engineered antibody Fc variants with enhanced effector function.
  5. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (Journal of Clinical Oncology)
  6. Potent antibody therapeutics by design (Nature reviews. Immunology)
  7. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  8. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (Journal of Clinical Oncology)
  9. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (Journal of the National Cancer Institute)
  10. A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

Their papers